The sixth annual open enrollment period for the Affordable Care Act kicks off today – and in less than a week, voters will go to the polls, where the future of health policy will be decided. Now more than ever, health care – and how it’s delivered – is top of mind for Americans.
In the final weeks preceding the 2018 midterm elections, Waxman Strategies’ Chairman and former Congressman Henry Waxman engaged in a series of interviews to elevate the benefits behind bipartisanship and the importance of effecting a credible and comprehensive investigation.
Today, we are excited to launch the Waxman Strategies Elections Hub, where we are sharing insights into the potential policy scenarios that could play out in November and beyond.
If it passes in Congress, the unfortunately named Hatch-Waxman Integrity Act of 2018 would ultimately delay generic drug competition and increase drug prices.
California Health Care Foundation (CHCF) interviews Waxman Strategies Chairman Henry Waxman on the changing political landscape of health care reform.
Former Congressman Henry Waxman (D-Calif.) and chairman of Waxman Strategies participated last weekend in the Aspen Institute’s annual Spotlight Health event to talk about rising prescription drug prices, as well as, reminisce on the Affordable Care Act (ACA).
Prescription drug prices have reached an all-time high. FDA Commissioner Gottlieb has taken on the issue indirectly, and announced several actions by the FDA intended to increase generic drug competition and transparency.
Democrats shouldn’t impose litmus tests on health care.
Today, the Commonwealth Fund published a blog post on the Bipartisan Budget Act of 2018, which will have an impact on Medicaid drug prices.